{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:47:06Z","timestamp":1792900026438,"version":"4.5.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2022JJ40253, 2021JJ40939, 2022JJ80043"],"award-info":[{"award-number":["2022JJ40253, 2021JJ40939, 2022JJ80043"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pembrolizumab, a programmed cell death protein 1 checkpoint inhibitor, is a novel drug used to treat a variety of advanced malignancies. However, it can also result in many immune-related adverse events, with cutaneous toxicities being the most frequent. Regarding pembrolizumab-induced skin adverse reactions, bullous pemphigoid (BP) has the worst effects on quality of life. Recently, there have been more and more reports of BP incidents resulting from pembrolizumab therapy in patients with cancer. This study aimed to define the clinical characteristics, diagnosis and management of pembrolizumab-induced BP and identify potential differences between classical BP and pembrolizumab-induced BP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Case reports, case series, and case analyses of pembrolizumab-induced BP up to 10 December 2022 were collected for retrospective analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our study included 47 patients (33 males and 14 females) from 40 studies. The median age was 72 years (range 42-86 years). The median time to cutaneous toxicity was 4 months (range 0.7-28 months), and the median time to bullae formation was 7.35 months (range 0.7-32 months). The most common clinical features were tense bullae and blisters (85.11%), pruritus (72.34%), and erythema (63.83%) on the limbs and trunk. In 20 of the 22 cases tested, the serum anti-BP180 autoantibodies were positive. However, in 10 cases (91.90%, 10\/11) the circulating autoantibodies of anti-BP230 were negative. 40 patients had skin biopsies and the skin biopsy revealed subepidermal bullae or blister eosinophil infiltration in 75.00% of patients with pembrolizumab-induced BP, 10.00% of patients with lymphocyte infiltration and 20.00% of patients with neutrophil infiltration. There were 20 patients (50%) with eosinophilic infiltration around the superficial dermis vessels, 8 patients (20.00%) with lymphocyte infiltration around the superficial dermis vessels, and 4 patients (10.00%) with neutrophil infiltration around the superficial dermis vessels. Direct immunofluorescence detected linear immunoglobulin G (IgG) IgG and\/or complement C3 along the dermo-epidermal junction in 36 patients (94.74%) with BP. IgG positivity was detected by indirect immunofluorescence in 81.82% of patients with BP. All patients were in complete remission (95.65%,44\/46) or partial remission (4.35%, 2\/46) of BP, whereas 9\/46 patients had a <jats:ext-link>relapse<\/jats:ext-link> or refractory. The majority of patients achieved BP remission after discontinuation of pembrolizumab with a combination of topically and systemically administered steroid treatments, or other medications. The median duration of BP remission was 2 months (range 0.3-15 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A thorough diagnosis of pembrolizumab-induced BP should be made using clinical signs, biochemical markers, histopathological and immunopathological tests. Pembrolizumab-induced BP had similar clinical characteristics to classic BP. Temporary or permanent discontinuation of pembrolizumab therapy may be required in patients with perbolizumab-induced BP depending on the severity of BP and the response to medication. Pembrolizumab-induced BP may be effectively treated using topical and systemic steroid treatments in combination with other medications (e.g., doxycycline, niacinamide, dapsone, rituximab, intravenous immunoglobulins, dupilumab, cyclophosphamide, methotrexate, mycophenolate mofetil, and infliximab). Clinicians should provide better management to patients with BP receiving pembrolizumab to prevent progression and ensure continuous cancer treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1095694","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T16:46:31Z","timestamp":1677861991000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid"],"prefix":"10.3389","volume":"13","author":[{"given":"Jianglin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six german dermatology centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14797","article-title":"Global incidence and prevalence of bullous pemphigoid: a systematic review and meta-analysis","volume":"21","author":"Lu","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14503","article-title":"Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios","volume":"45","author":"Kridin","year":"2018","journal-title":"J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in england 1998-2017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2930","article-title":"Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis","volume":"99","author":"Kridin","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.01.006","article-title":"Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies","volume":"31","author":"Lo","year":"2013","journal-title":"Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S267573","article-title":"Strategies to improve outcomes of bullous pemphigoid: a comprehensive review of clinical presentations, diagnosis, and patients\u2019 assessment","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1423\u2013","DOI":"10.1590\/1806-9282.65.12.1423","article-title":"Advanced non-small cell lung cancer - treatment with pembrolizumab","author":"Silvinato","year":"1992","journal-title":"Rev Assoc Med Bras"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1389200223666220609125013","article-title":"Review of the clinical pharmacokinetics, efficacy and safety of pembrolizumab","volume":"23","author":"Homsek","year":"2022","journal-title":"Curr Drug Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the keynote-010, keynote-024, and keynote-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946370","article-title":"Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: a case report and review of literature","volume":"27","author":"Cosimati","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731774","article-title":"Case report: a rare case of pembrolizumab-induced bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.02.008","article-title":"Pembrolizumab-induced bullous pemphigoid","volume":"5","author":"Sun","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e15623","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e21770","DOI":"10.7759\/cureus.21770","article-title":"Bullous pemphigoid associated with pembrolizumab therapy for non-small-cell lung cancer: a case report","volume":"14","author":"Chatterjee","year":"2022","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000489661","article-title":"Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports","volume":"10","author":"Thomsen","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/1346-8138.15140","article-title":"Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: a case report","volume":"47","author":"Muto","year":"2020","journal-title":"J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15796","article-title":"Bullous pemphigoid probably associated with pembrolizumab: a case of delayed toxicity","volume":"61","author":"Correia","year":"2022","journal-title":"Int J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.03.003","article-title":"Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis","volume":"6","author":"Qiu","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000514144","article-title":"Refractory bullous pemphigoid in a patient with metastatic lung adenocarcinoma treated with pembrolizumab","volume":"14","author":"Cardona","year":"2021","journal-title":"Case Rep Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-016-0123-3","article-title":"Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid","volume":"4","author":"Beck","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15693","article-title":"Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment","volume":"48","author":"Sugawara","year":"2021","journal-title":"J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14813","article-title":"Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab","volume":"46","author":"Adachi","year":"2019","journal-title":"J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2090","article-title":"Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient","volume":"7","author":"Honigman","year":"2019","journal-title":"Clin Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13411","article-title":"Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma","volume":"16","author":"Amber","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01396-5","article-title":"Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report","volume":"14","author":"Eguchi","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13940","article-title":"Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen xvii","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12488","article-title":"Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma","volume":"58","author":"Parakh","year":"2017","journal-title":"Australas J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000191","article-title":"Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer","volume":"41","author":"Garje","year":"2018","journal-title":"J Immunother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14179","article-title":"Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology","volume":"31","author":"Bandino","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10159","article-title":"Pruritus and tense bullae after discontinuation of pembrolizumab in a patient with renal cell carcinoma","volume":"324","author":"Bieber","year":"2020","journal-title":"Jama"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.13735\/j.cjdv.1001-7089.202102028","article-title":"Treatment of bullous pemphigoid with PD-1 inhibitors: a case report","author":"Gu","year":"2022","journal-title":"Chin J Dermatovenereol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000514806","article-title":"A late dermatologic presentation of bullous pemphigoid induced by anti-PD-1 therapy and associated with unexplained neurological disorder","volume":"14","author":"Wang","year":"2021","journal-title":"Case Rep Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15366","article-title":"Pembrolizumab-induced reactivation of bullous pemphigoid","volume":"60","author":"Kaul","year":"2021","journal-title":"Int J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00751","article-title":"Pembrolizumab-induced bullous pemphigoid treated with rituximab","volume":"16","author":"Sharma","year":"2020","journal-title":"Jco Oncol Pract"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3264-19","article-title":"Bullous pemphigoid in a patient treated with pembrolizumab","volume":"59","author":"Hara","year":"2020","journal-title":"Intern Med"},{"key":"B46","article-title":"Bullous pemphigoid associated with pembrolizumab therapy for metastatic adenocarcinoma of the lung","volume":"183","author":"Lawless","year":"2020","journal-title":"Br J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S736","DOI":"10.1016\/j.jtho.2019.08.1576","article-title":"Bullous pemphigoid: a rare immunomediated event secondary to immunotherapy in a patient with metastatic lung cancer","volume":"14","author":"Vissotto","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B48","first-page":"E151","article-title":"A blistering eruption following pembrolizumab therapy for metastatic melanoma","volume":"180","author":"Soriano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B49","doi-asserted-by":"crossref","first-page":"B218","DOI":"10.1016\/j.jaad.2018.05.873","article-title":"Pembrolizumab-induced bullous pemphigoid","volume":"79","author":"Kartha","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12484","article-title":"Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab","volume":"57","author":"Lomax","year":"2016","journal-title":"Australas J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"446018117","DOI":"10.1177\/2054270418793029","article-title":"Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma","volume":"9","author":"Hanley","year":"2018","journal-title":"JRSM Open"},{"key":"B52","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.12788\/cutis.0011","article-title":"Anti-PD-1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer","volume":"105","author":"Schwartzman","year":"2020","journal-title":"Cutis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.3390\/cancers14215451","article-title":"A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors","volume":"14","author":"Shalata","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk factors for the development of bullous pemphigoid in us patients receiving immune checkpoint inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage iii melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"20038","DOI":"10.1038\/s41598-022-24286-3","article-title":"Cutaneous adverse events in patients treated with PD-1\/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2022","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14594","article-title":"Sex differences in the characteristics and survival of patients with non-small-cell lung cancer: a retrospective analytical study based on real-world clinical data of the korean population","volume":"13","author":"Jeon","year":"2022","journal-title":"Thorac Cancer"},{"key":"B60","article-title":"SEER cancer statistics review","author":"Noone","year":""},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex differences in tolerability to anti-programmed cell death protein 1 therapy in patients with metastatic melanoma and non-small cell lung cancer: are we all equal","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in france","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"Bmj"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in switzerland: a 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/etm.2021.10972","article-title":"Bullous pemphigoid: an immune disorder related to aging (review)","volume":"23","author":"Deotto","year":"2022","journal-title":"Exp Ther Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1619693","article-title":"Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the fda adverse event reporting system","volume":"18","author":"Aggarwal","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"v377","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific igg is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb02665.x","article-title":"Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia","volume":"133","author":"Fairley","year":"1995","journal-title":"Br J Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-012-0981-9","article-title":"Collagen xvii is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis","volume":"138","author":"Krenacs","year":"2012","journal-title":"Histochem Cell Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/CMR.0000000000000500","article-title":"Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature","volume":"28","author":"Zhao","year":"2018","journal-title":"Melanoma Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid","volume":"16","author":"Bagci","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: a population-based case-control study","volume":"131","author":"Langan","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: Trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.062","article-title":"Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: a single-center retrospective review","volume":"81","author":"Wang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced nsclc treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1057096","article-title":"Bullous pemphigoid-what do we know about the most recent therapies","volume":"9","author":"Zeng","year":"2022","journal-title":"Front Med (Lausanne)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1095694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T16:46:39Z","timestamp":1677861999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1095694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":85,"alternative-id":["10.3389\/fonc.2023.1095694"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1095694","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"article-number":"1095694"}}